Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EZH2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/EZH2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EZH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EZH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EZH2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EZH2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EZH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190199115 | Thyroid | ATC | negative regulation of mitotic cell cycle phase transition | 94/6293 | 179/18723 | 1.33e-07 | 2.19e-06 | 94 |
GO:007030122 | Thyroid | ATC | cellular response to hydrogen peroxide | 58/6293 | 98/18723 | 1.81e-07 | 2.86e-06 | 58 |
GO:004593015 | Thyroid | ATC | negative regulation of mitotic cell cycle | 117/6293 | 235/18723 | 1.93e-07 | 3.05e-06 | 117 |
GO:004484316 | Thyroid | ATC | cell cycle G1/S phase transition | 119/6293 | 241/18723 | 2.68e-07 | 4.10e-06 | 119 |
GO:003424314 | Thyroid | ATC | regulation of transcription elongation from RNA polymerase II promoter | 25/6293 | 32/18723 | 3.13e-07 | 4.68e-06 | 25 |
GO:005076723 | Thyroid | ATC | regulation of neurogenesis | 168/6293 | 364/18723 | 3.73e-07 | 5.48e-06 | 168 |
GO:0016358110 | Thyroid | ATC | dendrite development | 119/6293 | 243/18723 | 4.65e-07 | 6.75e-06 | 119 |
GO:000008216 | Thyroid | ATC | G1/S transition of mitotic cell cycle | 107/6293 | 214/18723 | 4.83e-07 | 6.99e-06 | 107 |
GO:004876221 | Thyroid | ATC | mesenchymal cell differentiation | 116/6293 | 236/18723 | 5.08e-07 | 7.30e-06 | 116 |
GO:004851124 | Thyroid | ATC | rhythmic process | 141/6293 | 298/18723 | 5.58e-07 | 7.93e-06 | 141 |
GO:009006817 | Thyroid | ATC | positive regulation of cell cycle process | 115/6293 | 236/18723 | 9.87e-07 | 1.29e-05 | 115 |
GO:006048521 | Thyroid | ATC | mesenchyme development | 136/6293 | 291/18723 | 2.04e-06 | 2.43e-05 | 136 |
GO:005196014 | Thyroid | ATC | regulation of nervous system development | 195/6293 | 443/18723 | 2.62e-06 | 3.06e-05 | 195 |
GO:001071821 | Thyroid | ATC | positive regulation of epithelial to mesenchymal transition | 34/6293 | 52/18723 | 2.76e-06 | 3.19e-05 | 34 |
GO:003450212 | Thyroid | ATC | protein localization to chromosome | 52/6293 | 92/18723 | 5.21e-06 | 5.61e-05 | 52 |
GO:009872722 | Thyroid | ATC | maintenance of cell number | 70/6293 | 134/18723 | 6.45e-06 | 6.69e-05 | 70 |
GO:001097614 | Thyroid | ATC | positive regulation of neuron projection development | 82/6293 | 163/18723 | 7.43e-06 | 7.61e-05 | 82 |
GO:004002913 | Thyroid | ATC | regulation of gene expression, epigenetic | 57/6293 | 105/18723 | 1.01e-05 | 1.00e-04 | 57 |
GO:003110023 | Thyroid | ATC | animal organ regeneration | 44/6293 | 76/18723 | 1.18e-05 | 1.15e-04 | 44 |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EZH2 | SNV | Missense_Mutation | | c.2168N>T | p.Thr723Ile | p.T723I | Q15910 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EZH2 | SNV | Missense_Mutation | novel | c.1475N>A | p.Thr492Asn | p.T492N | Q15910 | protein_coding | tolerated(0.27) | probably_damaging(0.997) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EZH2 | insertion | In_Frame_Ins | novel | c.940_941insGAACAAGAATATTAACAAAAATAAAACGAACATTAG | p.Lys314delinsArgThrArgIleLeuThrLysIleLysArgThrLeuGlu | p.K314delinsRTRILTKIKRTLE | Q15910 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EZH2 | SNV | Missense_Mutation | novel | c.1903G>T | p.Asp635Tyr | p.D635Y | Q15910 | protein_coding | deleterious(0.05) | probably_damaging(0.94) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EZH2 | SNV | Missense_Mutation | | c.1090N>T | p.Pro364Ser | p.P364S | Q15910 | protein_coding | tolerated(0.48) | benign(0.178) | TCGA-C5-A1M9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
EZH2 | SNV | Missense_Mutation | | c.877N>C | p.Asp293His | p.D293H | Q15910 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EX-A69L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EZH2 | SNV | Missense_Mutation | | c.2084C>T | p.Ser695Leu | p.S695L | Q15910 | protein_coding | deleterious(0.05) | probably_damaging(0.994) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EZH2 | SNV | Missense_Mutation | | c.1760C>T | p.Pro587Leu | p.P587L | Q15910 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-2679-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EZH2 | SNV | Missense_Mutation | | c.926N>G | p.Asn309Ser | p.N309S | Q15910 | protein_coding | tolerated(0.17) | possibly_damaging(0.881) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EZH2 | SNV | Missense_Mutation | | c.451N>C | p.Lys151Gln | p.K151Q | Q15910 | protein_coding | deleterious(0.01) | possibly_damaging(0.727) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | GSK2816126 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-55 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | inhibitor | 178103592 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-54 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-20 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | DZNeP | | 25605023 |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-17 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-40 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | PMID28394193-Compound-12 | | |
2146 | EZH2 | CLINICALLY ACTIONABLE, ENZYME, METHYL TRANSFERASE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | inhibitor | 178103590 | TAZEMETOSTAT | |